Feb 20th 2013 - Edison Investment Research today published a report on Lombard Medical Technologies (LMT.L, LSE:LMT, LON:LMT) entitled "Aorfix Wins FDA Approval". In summary, the report says:
Lombard Medical has received the long-awaited FDA approval for its Aorfix endovascular aortic stent graft for treatment of abdominal aortic aneurysm (AAA). The US approval is a significant landmark in Lombard’s more than a decade-long development of the Aorfix device. It is also the trigger event for a pre-agreed £14.1m financing, which will support the launch of the product. The US label includes treatment of patients with aortic neck angulations of 0-90˚, a uniquely broad label claim. We have increased our valuation of Lombard to £104.7m or 346p/share, adjusting for the 10.1m shares to be issued in fundraising.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »